Article
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Blood - 15 May 2004
Smith B Douglas, Levis Mark, Beran Miloslav, Giles Francis, Kantarjian Hagop, Berg Karin, Murphy Kathleen M, Dauses Tianna, Allebach Jeffrey, Small Donald
Abstract excerpt
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 inhibition can also...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.